The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Madopar 50 mg/12.5 mg dispersible tablets



Roche Products (Ireland) Ltd PA2307/004/002

Main Information

Trade NameMadopar 50 mg/12.5 mg dispersible tablets
Active SubstancesLevodopa
Benserazide
Dosage FormDispersible tablet
Licence HolderRoche Products (Ireland) Ltd
Licence NumberPA2307/004/002

Group Information

ATC CodeN04BA Dopa and dopa derivatives
N04BA02 levodopa and decarboxylase inhibitor

Status

Authorised/WithdrawnAuthorised
Licence Issued08/04/1987
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back